{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:31:48Z","timestamp":1785522708852,"version":"3.56.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In this era of adoption of novel biomarkers such as circulating tumor DNA (ctDNA) to monitor the risk of relapse or detect early progression, and renewed enthusiasm for previously studied biomarkers such as pathological complete response rates (pCR), there is growing confusion regarding the utility of these biomarkers to predict outcomes at both individual-level and trial levels. This distinction between prognostic and predictive utility of biomarkers is important because misunderstanding between the two can lead to incorrect clinical inferences and misguided regulatory decisions. In this commentary, we discuss how to distinguish between prognostic and predictive biomarkers, when to consider them strong enough to be a surrogate endpoint in clinical trials, and whether they should change clinical practice. We use examples from DESTINY-Breast11, SERENA-6, DYNAMIC-III, and IMvigor011 trials to elucidate these points. Destiny-Breast 11, SERENA-6, and IMvigor011 have recently been topics of debate at the FDA, with the FDA offering approvals based on both Destiny-Breast 11 and IMvigor011, while the Oncology Drug Advisory Committee voting against approval based on SERENA-6.<\/jats:p>","DOI":"10.1093\/jnci\/djag174","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:49:47Z","timestamp":1780055387000},"source":"Crossref","is-referenced-by-count":1,"title":["Critical appraisal: prognostic versus predictive surrogate markers in oncology"],"prefix":"10.1093","author":[{"given":"Aliyah","family":"Pabani","sequence":"first","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University , Baltimore, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7444-8594","authenticated-orcid":false,"given":"Bishal","family":"Gyawali","sequence":"additional","affiliation":[{"name":"Division of Cancer Care and Epidemiology, Sinclair Cancer Research Institute, Queen\u2019s University , Kingston, Ontario,","place":["Canada"]},{"name":"Department of Oncology, Queen\u2019s University , Kingston, Ontario,","place":["Canada"]},{"name":"Ontario Institute for Cancer Research , Toronto, Ontario,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"2026061819342837400_djag174-B1","doi-asserted-by":"publisher","first-page":"100332","DOI":"10.1016\/j.eclinm.2020.100332","article-title":"Evaluating the evidence behind the surrogate measures included in the FDA\u2019s table of surrogate endpoints as supporting approval of cancer drugs","volume":"21","author":"Gyawali","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2026061819342837400_djag174-B2","doi-asserted-by":"publisher","first-page":"102824","DOI":"10.1016\/j.eclinm.2024.102824","article-title":"Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward","volume":"76","author":"Mittal","year":"2024","journal-title":"eClinicalMedicine"},{"key":"2026061819342837400_djag174-B3","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1200\/JCO.2015.63.3651","article-title":"Biomarker: predictive or Prognostic?","volume":"33","author":"Ballman","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026061819342837400_djag174-B4","doi-asserted-by":"publisher","first-page":"pkz002","DOI":"10.1093\/jncics\/pkz002","article-title":"A systematic review and recommendation for reporting of surrogate endpoint evaluation using meta-analyses","volume":"3","author":"Xie","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"2026061819342837400_djag174-B5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","article-title":"The validation of surrogate endpoints in meta-analyses of randomized experiments","volume":"1","author":"Buyse","year":"2000","journal-title":"Biostatistics"},{"key":"2026061819342837400_djag174-B6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/oncolo\/oyac006","article-title":"Surrogacy beyond prognosis: the importance of \u201cTrial-Level\u201d surrogacy","volume":"27","author":"Buyse","year":"2022","journal-title":"Oncologist"},{"key":"2026061819342837400_djag174-B7","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1001\/jamaoncol.2022.3755","article-title":"Surrogacy of pathologic complete response in trials of neoadjuvant therapy for early breast cancer: critical analysis of strengths, weaknesses, and misinterpretations","volume":"8","author":"Conforti","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026061819342837400_djag174-B8","doi-asserted-by":"publisher","first-page":"102283","DOI":"10.1016\/j.eclinm.2023.102283","article-title":"A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials","volume":"65","author":"Ciani","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026061819342837400_djag174-B9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/s0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"2026061819342837400_djag174-B10","doi-asserted-by":"publisher","first-page":"e066381","DOI":"10.1136\/bmj-2021-066381","article-title":"Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis","volume":"375","author":"Conforti","year":"2021","journal-title":"BMJ"},{"key":"2026061819342837400_djag174-B11","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S1470-2045(25)00546-7","article-title":"Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials","volume":"26","author":"Conforti","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026061819342837400_djag174-B12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"2026061819342837400_djag174-B13","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","article-title":"3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial","volume":"403","author":"P\u00e9rez-Garc\u00eda","year":"2024","journal-title":"Lancet"},{"key":"2026061819342837400_djag174-B14","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck","year":"2026","journal-title":"Ann Oncol"},{"key":"2026061819342837400_djag174-B15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026061819342837400_djag174-B16","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026061819342837400_djag174-B17","doi-asserted-by":"publisher","first-page":"102390","DOI":"10.1016\/j.esmoop.2024.102390","article-title":"Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis","volume":"9","author":"Nader-Marta","year":"2024","journal-title":"ESMO Open"},{"key":"2026061819342837400_djag174-B18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13058-025-01986-y","article-title":"Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis","volume":"27","author":"Zhang","year":"2025","journal-title":"Breast Cancer Res"},{"key":"2026061819342837400_djag174-B19","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann Oncol"},{"key":"2026061819342837400_djag174-B20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2023.11.009","article-title":"Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort","volume":"35","author":"Henriksen","year":"2024","journal-title":"Ann Oncol"},{"key":"2026061819342837400_djag174-B21","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ejca.2020.11.025","article-title":"Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis","volume":"144","author":"Jones","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026061819342837400_djag174-B22","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1158\/1078-0432.CCR-17-0510","article-title":"Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer","volume":"23","author":"Sch\u00f8ler","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026061819342837400_djag174-B23","doi-asserted-by":"publisher","first-page":"102999","DOI":"10.1016\/j.ctrv.2025.102999","article-title":"Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: a systematic review and meta-analysis","volume":"139","author":"Holz","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"2026061819342837400_djag174-B24","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1038\/s41591-025-04030-w","article-title":"Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2\/3 DYNAMIC-III trial","volume":"31","author":"Tie","year":"2025","journal-title":"Nat Med"},{"key":"2026061819342837400_djag174-B25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"key":"2026061819342837400_djag174-B26","author":"Fierce Biotech"},{"key":"2026061819342837400_djag174-B27","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"2026061819342837400_djag174-B28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag174\/68446102\/djag174.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag174\/68446102\/djag174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:34:33Z","timestamp":1781825673000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article\/doi\/10.1093\/jnci\/djag174\/8699623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":28,"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag174","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"article-number":"djag174"}}